Companies Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals (ABOS): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Acumen Pharmaceuticals, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,930,011FY2023
- $4,780,687FY2024
- $1,863,567FY2025
CEO total pay was $1,863,567 in fiscal 2025, down from $4,780,687 in fiscal 2024.
FY2025: salary $646,354 · bonus $0 · stock awards $412,482 · option awards $478,338
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel O'Connell | $646,354 | $0 | $412,482 | $478,338 | $305,725 | $0 | $20,668 | $1,863,567 |
| Chief Executive Officer | ||||||||
| Jim Doherty | 520,000 | 0 | 115,070 | 133,419 | 223,600 | 0 | 20,770 | 1,012,859 |
| President and Chief Development Officer | ||||||||
| Matthew Zuga | 486,993 | 0 | 123,580 | 143,429 | 172,980 | 0 | 21,807 | 948,789 |
| Chief Financial Officer and Chief Business Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel O'Connell | $1,863,567 | $4,780,687 | $3,930,011 | ↓ −2,917,120 |
| Jim Doherty | 1,012,859 | 2,182,081 | — | ↓ −1,169,222 |
| Matthew Zuga | 948,789 | 1,689,514 | 1,606,289 | ↓ −740,725 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | — |
| Anti-hedging | true |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Matthew Zuga | Option | 3,125 | 5.19 | — |
| Daniel O'Connell | Option | 9,480 | 5.19 | — |
| Matthew Zuga | RSU | 11,167 | — | 23,562 |
| Daniel O'Connell | RSU | 38,000 | — | 80,180 |
| Matthew Zuga | Option | 40,842 | 6.11 | — |
| Jim Doherty | RSU | 62,200 | — | 131,242 |
| Matthew Zuga | RSU | 66,800 | — | 140,948 |
| Matthew Zuga | RSU | 70,666 | — | 149,105 |
| Jim Doherty | Option | 71,919 | 1.85 | — |
| Matthew Zuga | Option | 77,315 | 1.85 | — |
| Matthew Zuga | Option | 82,813 | 4.23 | — |
| Daniel O'Connell | Option | 127,969 | 6.11 | — |
| Daniel O'Connell | RSU | 225,400 | — | 475,594 |
| Daniel O'Connell | Option | 260,542 | 1.83 | — |
| Daniel O'Connell | RSU | 267,333 | — | 564,073 |
| Daniel O'Connell | Option | 313,542 | 4.23 | — |
| Jim Doherty | Option | 325,542 | 3.11 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Sean StalfortIndependent · Audit · Compensation | $77,935 | $13,696 | $15,415 | — | — | $107,046 |
| Kimberlee C. DrapkinIndependent · Audit (Chair) · Compensation | 60,000 | 13,696 | 15,415 | — | — | 89,111 |
| Laura StoppelIndependent · Audit · Nominating and Corporate Governance (Chair) | 55,500 | 13,696 | 15,415 | — | — | 84,611 |
| George GolumbeskiIndependent · Board Chair | 10,652 | 0 | 72,090 | — | — | 82,742 |
| Jeffrey L. IvesIndependent · Compensation (Chair) | 50,000 | 13,696 | 15,415 | — | — | 79,111 |
| Derrell PorterIndependent · Nominating and Corporate Governance | 44,000 | 13,696 | 15,415 | — | — | 73,111 |
| Nathan B. FountainIndependent · Nominating and Corporate Governance | 44,000 | 13,696 | 15,415 | — | — | 73,111 |
| Daniel O'ConnellEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $342,087 |
| Equity awards (grant-date value) | $82,176 |
| All other compensation | $0 |
| Total cost of the board | $424,263 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Acumen Pharmaceuticals as a peer
Companies that benchmark against ABOS
2 companies name ABOS as a compensation peer
The list of companies that name ABOS as a peer is temporarily unavailable — recheck shortly.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Acumen Pharmaceuticals, Inc. | 2025 | Daniel O'Connell | $646,354 | $412,482 | $478,338 | $305,725 | $1,863,567 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2022 | 2022-06-15 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2022 | 2022-06-15 | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel O'Connell. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 32. As printed: 1,863,567. View filing ↗
- Section 01, Jim Doherty. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 32. As printed: 1,012,859. View filing ↗
- Section 01, Matthew Zuga. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 32. As printed: 948,789. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-26. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Sean Stalfort. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 107,046. View filing ↗
- Section 08, Kimberlee C. Drapkin. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 89,111. View filing ↗
- Section 08, Laura Stoppel. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 84,611. View filing ↗
- Section 08, George Golumbeski. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 82,742. View filing ↗
- Section 08, Jeffrey L. Ives. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 79,111. View filing ↗
- Section 08, Derrell Porter. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 73,111. View filing ↗
- Section 08, Nathan B. Fountain. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 73,111. View filing ↗
- Section 08, Daniel O'Connell. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2022 vote. Form 8-K, filed 2022-06-21. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 342,087 + equity 82,176 + all other 0 = 424,263, summed across the director compensation table rows.
- Acumen Pharmaceuticals, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Acumen Pharmaceuticals, Inc.'s own proxy. As printed: 1,863,567. View filing ↗